Key result
Use of dexrazoxane was associated with a significantly reduced risk of cardiac events in patients receiving CHOP/R-CHOP for aggressive non-Hodgkin's lymphoma (HR 0.1; 95% CI 0.01-0.75; P=0.02).
Why the study?
Does dexrazoxane prevent cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma receiving CHOP/R-CHOP chemotherapy?
Cohort (n=180)
Does dexrazoxane prevent cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma receiving CHOP/R-CHOP chemotherapy?
Effect estimate: HR 0.1 (95% CI 0.01-0.75)
p-value: p=0.02
Dexrazoxane may effectively prevent doxorubicin-induced cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma receiving CHOP/R-CHOP regimens.
No takes yet. Share an insight, caveat, or question.
May support dexrazoxane consideration to reduce cardiac events with CHOP; leaves open confirmation in randomized trials.
Limat et al. (2014) conducted a cohort in aggressive non-Hodgkin's lymphoma (n=180). dexrazoxane vs. no dexrazoxane was evaluated on cardiac events (decline in resting LVEF <50%, decline in LVEF ≥20% from baseline, or clinical evidence of CHF) (HR 0.1, 95% CI 0.01-0.75, p=0.02). Use of dexrazoxane was associated with a significantly reduced risk of cardiac events in patients receiving CHOP/R-CHOP for aggressive non-Hodgkin's lymphoma (HR 0.1; 95% CI 0.01-0.75; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: